MELVILLE, N.Y. — March 4, 2026 — Leads & Copy — BioRestorative Therapies, Inc. (NASDAQ:BRTX) announced a letter to shareholders from CEO Lance Alstodt, highlighting key achievements and future priorities.
The company is poised for growth, Alstodt noted, citing the completion of enrollment in the Phase 2 trial of BRTX-100, a positive Type B regulatory outcome, the initiation of Phase 3 enabling activities, a strengthened capital position after a $5 million public offering, an accelerating BioCosmeceutical strategy, and continued development of the ThermoStem® metabolic platform.
Each milestone is value-creating, said Alstodt. He added that together, they represent a convergence of clinical, regulatory and commercial momentum.
In February 2026, BioRestorative completed enrollment of 99 patients across 15 U.S. sites in its Phase 2 trial of BRTX-100 for chronic lumbar disc disease (cLDD). The company said this study is the largest and most rigorously designed FDA-authorized cell therapy trial conducted in cLDD.
Alstodt noted that the sham-controlled design establishes a high evidentiary threshold, aligning with registrational expectations and payer scrutiny in spine medicine. Rapid enrollment reflects clinical demand and site engagement, underscoring the unmet need and commercial opportunity. Topline results are expected after database lock and statistical analysis, he said.
BioRestorative held a Type B meeting with the FDA, confirming alignment on the proposed Phase 3 trial design, endpoints, dosing strategy, sample size, and powering assumptions. The company said no safety concerns were raised, and the Chemistry, Manufacturing, and Controls (CMC) framework was deemed appropriate for late-stage development.
According to Alstodt, regulatory alignment reduces development pathway uncertainty and allows the company to initiate Phase 3 enabling activities with confidence. BioRestorative is targeting submission of a Phase 3 IND amendment in the second half of 2026.
BioRestorative’s BioCosmeceutical platform is designed as a core element of its capital strategy and near-term revenue plan. The company is expanding distribution of products powered by its secretome-based biologics platform. The company said the appointment of Crystal Romano as Head of Global Commercial Operations will strengthen execution capabilities and accelerate commercialization.
BioRestorative is building a vertically integrated regenerative beauty platform engineered for scale, credibility, and monetization. A three-channel strategy includes global distribution partnerships, enterprise clinical adoption, and a direct-to-consumer engine, said the company.
The ThermoStem® platform, which focuses on brown adipose-derived stem cell (BADSC) therapies for metabolic disorders, continues to expand its intellectual property estate. The company recently received patent allowance in Australia covering the generation of non-naturally occurring three-dimensional brown adipose-derived stem cell aggregates.
Following the recent $5 million public offering, BioRestorative has strengthened its balance sheet and extended its operational runway. The company will advance BRTX-100 through key data readouts while preserving leverage ahead of potential partnership discussions, said Alstodt.
In 2026, BioRestorative’s primary focus is advancing BRTX-100 into late-stage development with regulatory clarity and BLA readiness. This includes Phase 3 enabling activities, protocol refinement, manufacturing readiness, and the Phase 3 IND amendment submission. The company plans to report Phase 2 topline results in early 2027.
BioRestorative intends to seek strategic and commercial partnerships within states like Utah, Wyoming, Texas, and Florida, where state laws allow providers to offer therapies like BRTX-100 prior to full BLA approval. The company will also continue to develop its BioCosmeceutical platform, focusing on execution and margin discipline.
BioRestorative remains committed to disciplined capital deployment aligned with clinical and regulatory milestones, extending operational runway, managing dilution, and preserving flexibility. Alstodt concluded that the company is transitioning from development-stage uncertainty toward late-stage regulatory clarity, with a focus on execution, data integrity, capital efficiency, and shareholder value.
Source: BioRestorative Therapies, Inc.
